Conclusions Extended BUP treatment relative to brief detoxification is cost effective in the US health-care system for the outpatient treatment of opioid-dependent youth. (Source: Addiction)

Conclusions  These results suggest that buprenorphine and buprenorphine/naloxone have similar abuse potential in non-dependent opioid abusers,
and that the addition of naloxone at these doses and in this dose ratio confers no evident advantage for decreasing the abuse
potential of intramuscular or sublingual buprenorphine in this population.

Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-010-1898-4Authors
Angela N. Duke, The Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences 5510 Nathan Shock Drive Baltimore MD 21224 USAChristopher J. Correia, The Johns Hopkins University School of Medicine Behavioral Pharmacology Research Unit, Department of Psychiatry and…

Abstract: Despite data supporting its efficacy, barriers to implementation of buprenorphine for office-based treatment are present. Complications can occur during buprenorphine inductions, yet few published studies have examined this phase of treatment. To examine factors associated with complications during buprenorphine induction, we conducted a retrospective chart review of the first 107 patients receiving buprenorphine treatment in an urban community health center. The primary outcome, defined as complicated induction (precipitated or protracted withdrawal), was observed in 18 (16.8%) patients. Complicated inductions were associated with poorer treatment retention (than routine inductions) and decreased over time. Factors independently associated with complicated inductions included re…

Major Finding: Office-based buprenorphine/naloxone treatment was associated with a statistically significant decrease in participants reporting illegal activity, from 19% to 2%, and in interacting with the legal system, from 16% to 1%. (Source: Family Practice News)

Major Finding: Office-based buprenorphine/naloxone treatment was associated with a statistically significant decrease in participants reporting illegal activity, from 19% to 2%, and in interacting with the legal system, from 16% to 1%. (Source: Internal Medicine News)

Conclusion: Management of HIV-infected, opioid-dependent patients with a clinic-based BUP strategy facilitates access to opioid agonist therapy and improves outcomes of substance abuse treatment. Primary Funding Source: Health Resources and Services Administration Special Projects of National Significance program.
PMID: 20513828 [PubMed – in process] (Source: Annals of Internal Medicine)

MINNEAPOLIS — Opioid-dependent patients with a history of incarceration do well with office-based buprenorphine/naloxone therapy and have fewer interactions over time with the legal and criminal justice systems, according to a data analysis of a previous randomized, controlled trial. (Source: Clinical Psychiatry News)

The objective was to achieve consensus on the conclusions to be drawn from this work. It was agreed that buprenorphine clearly behaves as a full [mu]-opioid agonist for analgesia in clinical practice, with no ceiling effect, but that there is a ceiling effect for respiratory depression, reducing the likelihood of this potentially fatal adverse event. This is entirely consistent with receptor theory. In addition, the effects of buprenorphine can be completely reversed by naloxone. No problems are encountered when switching to and from buprenorphine and other opioids, or in combining them. Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain. Other beneficial properties are the compound’s favorable safety pr…

Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients). The Probuphine and placebo arms will be double blinded, while the Suboxone arm will be open-label… (Source: Health News from Medical News Today)

Updated Date: Mar 31, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))